MYGN Quote, Financials, Valuation and Earnings

Atossa Therapeutics, Inc. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of --. Myriad Genetics, Inc.'s return on equity of -69.09% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.

Myriad Genetics, Inc. has a consensus price target of $8.52, signalling upside risk potential of 16.24%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 648.85%. Given that Atossa Therapeutics, Inc. has higher upside potential than Myriad Genetics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Myriad Genetics, Inc..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.148% more volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 0.950, suggesting its less volatile than the S&P 500 by 4.956%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are larger than Atossa Therapeutics, Inc. quarterly revenues of --. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.82x versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Celldex Therapeutics, Inc. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of -7753.43%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Myriad Genetics, Inc. has a consensus price target of $8.52, signalling upside risk potential of 16.24%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.14 which suggests that it could grow by 79.54%. Given that Celldex Therapeutics, Inc. has higher upside potential than Myriad Genetics, Inc., analysts believe Celldex Therapeutics, Inc. is more attractive than Myriad Genetics, Inc..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.148% more volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.281%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are larger than Celldex Therapeutics, Inc. quarterly revenues of --. Myriad Genetics, Inc.'s net income of -$27.4M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.82x versus 755.79x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neogen Corp. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 17.37%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Neogen Corp.'s return on equity of -41.21%.

Myriad Genetics, Inc. has a consensus price target of $8.52, signalling upside risk potential of 16.24%. On the other hand Neogen Corp. has an analysts' consensus of $8.17 which suggests that it could grow by 37.49%. Given that Neogen Corp. has higher upside potential than Myriad Genetics, Inc., analysts believe Neogen Corp. is more attractive than Myriad Genetics, Inc..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.148% more volatile than S&P 500. In comparison Neogen Corp. has a beta of 1.986, suggesting its more volatile than the S&P 500 by 98.621%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neogen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Neogen Corp. pays out -- of its earnings as a dividend.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than Neogen Corp. quarterly revenues of $209.2M. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Neogen Corp.'s net income of $36.3M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Neogen Corp.'s PE ratio is 2,124.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.82x versus 1.45x for Neogen Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -13.32% compared to Myriad Genetics, Inc.'s net margin of 7.29%. Myriad Genetics, Inc.'s return on equity of -69.09% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Myriad Genetics, Inc. has a consensus price target of $8.52, signalling upside risk potential of 16.24%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Myriad Genetics, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Myriad Genetics, Inc. is more attractive than Phibro Animal Health Corp..

Myriad Genetics, Inc. has a beta of 1.811, which suggesting that the stock is 81.148% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Myriad Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Myriad Genetics, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Myriad Genetics, Inc. quarterly revenues are $205.7M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Myriad Genetics, Inc.'s net income of -$27.4M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Myriad Genetics, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myriad Genetics, Inc. is 0.82x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.